Search Result
Results for "
L-glutamic
" in MedChemExpress (MCE) Product Catalog:
9
Biochemical Assay Reagents
33
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-14608
-
|
|
Environmental Pollutants
Endogenous Metabolite
iGluR
Ferroptosis
Apoptosis
|
Neurological Disease
|
|
L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases. L-Glutamic acid acts at ionotropic and metabotropic glutamate receptors .
|
-
-
- HY-N0390
-
-
-
- HY-14608A
-
|
|
Environmental Pollutants
iGluR
Apoptosis
Ferroptosis
Endogenous Metabolite
|
Neurological Disease
|
|
L-Glutamic acid monosodium salt is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium salt has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium salt can be used in the study of neurological diseases. L-Glutamic acid monosodium salt acts at ionotropic and metabotropic glutamate receptors .
|
-
-
- HY-N0390S1
-
|
L-glutamic acid 5-amide-13C5
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
L-Glutamine- 13C5 is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
|
-
-
- HY-15121
-
|
L-glutamic Acid γ-ethyl amide; Nγ-Ethyl-L-glutamine
|
Apoptosis
Endogenous Metabolite
Reactive Oxygen Species (ROS)
|
Neurological Disease
Cancer
|
|
L-Theanine (L-Glutamic Acid γ-ethyl amide) is a non-protein amino acid contained in green tea leaves, which blocks the binding of L-glutamic acid to glutamate receptors in the brain, and with neuroprotective, anticancer and anti-oxidative activities. L-Theanine can pass through the blood–brain barrier and is orally active .
|
-
-
- HY-N0390S
-
|
L-glutamic acid 5-amide-15N
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
L-Glutamine- 15N is the 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
|
-
-
- HY-14608S5
-
|
|
Endogenous Metabolite
iGluR
Ferroptosis
Apoptosis
|
Neurological Disease
|
|
L-Glutamic acid- 13C5 is the 13C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
|
-
-
- HY-N0390S8
-
|
L-glutamic acid 5-amide-15N2
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
L-Glutamine- 15N2 is the 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
|
-
-
- HY-B0711
-
|
N-Carbamyl-L-glutamic acid
|
Carbamoyl Phosphate Synthetase (CPS)
|
Cancer
|
|
Carglumic acid (N-Carbamyl-L-glutamic acid), a functional analogue of N-acetylglutamate (NAG) and a carbamoyl phosphate synthetase 1 (CPS1) activator, is used to treat acute and chronic hyperammonemia associated with NAG synthase (NAGS) deficiency.
|
-
-
- HY-14608S7
-
|
|
Endogenous Metabolite
iGluR
Ferroptosis
Apoptosis
|
Neurological Disease
|
|
L-Glutamic acid-d5 is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
|
-
-
- HY-N0390S9
-
|
L-glutamic acid 5-amide-15N-1
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
L-Glutamine- 15N-1 is the 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
|
-
-
- HY-W015240
-
|
|
Endogenous Metabolite
|
Metabolic Disease
Inflammation/Immunology
|
|
N-Acetyl-L-glutamic acid is a type of glutamic acid that can serve as a component of cell culture media. When combined with media containing inorganic salts, carbohydrates, vitamins, and amino acids, N-Acetyl-L-glutamic acid plays roles in promoting cell growth, enhancing antibody production, etc. N-Acetyl-L-glutamic acid is also an endogenous metabolite that can be found in the brain. Additionally, as an IgE blocker, N-Acetyl-L-glutamic acid can be used in the research of allergic diseases .
|
-
-
- HY-14608S8
-
|
|
Endogenous Metabolite
iGluR
Ferroptosis
Apoptosis
|
Neurological Disease
|
|
L-Glutamic acid-d3 is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
|
-
-
- HY-14608S3
-
-
-
- HY-100815B
-
|
(±)-AMPA
|
iGluR
|
Neurological Disease
|
|
(RS)-AMPA ((±)-AMPA) is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA does not interfere with binding sites for kainic acid or NMDA receptors .
|
-
-
- HY-14608R
-
|
|
Reference Standards
Endogenous Metabolite
iGluR
Ferroptosis
Apoptosis
|
Neurological Disease
|
L-Glutamic acid (Standard) is the analytical standard of L-Glutamic acid. This product is intended for research and analytical applications. L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases .
IC50 & Target:DA .
In Vitro: L-Glutamic acid (120, 500, 750, 1000 mg/dL) can reduce the harmful effect of lithium on the embryonic development of Xenopus Xenopus .
L-Glutamic acid (2, 5, 10, 20 mM, 24-48 h) can induce neuroexcitotoxicity in neuroblastoma .
In Vivo: L-Glutamic acid (3 g/kg, subcutaneous injection) can promote excitotoxic degeneration of retinal ganglion cells in mice .
L-Glutamic acid (750 mg/kg, intraperitoneal injection) can reduce and inhibit oxidative stress induced by chlorpyrifos (CPF) in rats .
|
-
-
- HY-N0390S2
-
|
L-glutamic acid 5-amide-d5
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
L-Glutamine-d5 is the deuterium labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
|
-
-
- HY-N0390S6
-
|
L-glutamic acid 5-amide-13C5,15N2
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
L-Glutamine- 13C5, 15N2 is the 13C- and 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
|
-
-
- HY-W141949
-
-
-
- HY-W419700
-
|
|
Endogenous Metabolite
iGluR
Ferroptosis
Apoptosis
|
Neurological Disease
|
|
L-Glutamic acid ammonium is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid ammonium has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases. L-Glutamic acid ammonium acts at ionotropic and?metabotropic glutamate receptors .
|
-
-
- HY-N0390R
-
|
L-glutamic acid 5-amide (Standard)
|
Reference Standards
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
L-Glutamine (Standard) is the analytical standard of L-Glutamine (HY-N0390). This product is intended for research and analytical applications. L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
|
-
-
- HY-W016145
-
|
|
Endogenous Metabolite
iGluR
Ferroptosis
Apoptosis
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
L-Glutamic acid monosodium hydrate is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium hydrate has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium hydrate can be used in the study of neurological diseases. L-Glutamic acid monosodium hydrate acts at ionotropic and?metabotropic glutamate receptors .
|
-
-
- HY-14608S
-
|
|
Endogenous Metabolite
iGluR
Ferroptosis
Apoptosis
|
Neurological Disease
|
|
L-Glutamic acid- 13C is the 13C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
|
-
-
- HY-N13356
-
|
gamma-Glutamylthreonine; H-γ-Glu-Thr-OH; γ-Glu-Thr
|
Bacterial
Peptide-Drug Conjugates (PDCs)
Drug Metabolite
|
Infection
Inflammation/Immunology
|
|
L-gamma-Glutamyl-L-threonine (gamma-Glutamylthreonine; H-γ-Glu-Thr-OH; γ-Glu-Thr) is a dipeptide obtained through the formal condensation of the L-glutamic acid side chain carboxyl group and the L-threonine amino group. L-gamma-Glutamyl-L-threonine is present in high concentrations in human urine and exhibits antibacterial activity against Gram-negative bacterial. L-gamma-Glutamyl-L-threonine is also a flavor compound. Gamma-Glutamylthreonine is a metabolite catalyzed by γ-glutamyl transpeptidase and is associated with immune regulation. Gamma-Glutamylthreonine can be used in research on inflammation and bacterial infections .
|
-
-
- HY-W337739
-
|
Monopotassium L-glutamate
|
Biochemical Assay Reagents
|
Others
|
|
L-Glutamic acid monopotassium salt is a food additive and flavor enhancer that can reduce the harmful effects of lithium .
|
-
-
- HY-W011713
-
-
-
- HY-15936
-
|
L-γ-Glutamyl-3-carboxy-4-nitroanilide ammonium salt
|
γ-Glutamyl Transferase (GGT)
|
Metabolic Disease
|
|
L-Glutamic acid γ-(3-carboxy-4-nitroanilide) ammonium salt is a donor substrate of gamma-glutamyltransferase (GGT) that can be used to measure GGT activity .
|
-
-
- HY-14608S2
-
|
|
Endogenous Metabolite
iGluR
Ferroptosis
Apoptosis
|
Neurological Disease
|
|
L-Glutamic acid- 15N is the 15N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals .
|
-
-
- HY-14608S1
-
|
|
Endogenous Metabolite
iGluR
Ferroptosis
Apoptosis
|
Neurological Disease
|
|
L-Glutamic acid-1- 13C is the 13C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
|
-
-
- HY-112111
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
Poly-L-Glutamic acid (MW 700000) is a compound carrier. Poly-L-Glutamic acid (MW 700000) can be used for the targeted delivery of anticancer compounds .
|
-
-
- HY-15121R
-
|
L-glutamic Acid γ-ethyl amide (Standard); Nγ-Ethyl-L-glutamine (Standard)
|
Reference Standards
Apoptosis
Endogenous Metabolite
Reactive Oxygen Species (ROS)
|
Neurological Disease
Cancer
|
|
L-Theanine (Standard) is the analytical standard of L-Theanine. This product is intended for research and analytical applications. L-Theanine (L-Glutamic Acid γ-ethyl amide) is a non-protein amino acid contained in green tea leaves, which blocks the binding of L-glutamic acid to glutamate receptors in the brain, and with neuroprotective, anticancer and anti-oxidative activities. L-Theanine can pass through the blood–brain barrier and is orally active .
|
-
-
- HY-N13258
-
|
β-Citrylglutamic acid
|
Others
|
Others
|
|
β-Citryl-L-glutamic acid (β-Citrylglutamic acid) is a citrylglutamic acid, that can be isolated from newborn rat brain .
|
-
-
- HY-42364
-
-
-
- HY-W015424
-
-
-
- HY-15121S
-
|
L-glutamic Acid γ-ethyl amide-d5; Nγ-Ethyl-L-glutamine-d5
|
Apoptosis
Endogenous Metabolite
|
Neurological Disease
|
|
L-Theanine-d5 is the deuterium labeled L-Theanine. L-Theanine (L-Glutamic Acid γ-ethyl amide)is a non-protein amino acid contained in green tea leaves, which blocks the binding of L-glutamic acid to glutamate receptors in the brain, and with neuroprotective and anti-oxidative activities. L-Theanine causes anti-stress effects via the inhibition of cortical neuron excitation by oral intake .
|
-
-
- HY-W041895S1
-
|
|
Endogenous Metabolite
|
Others
|
|
DL-Glutamic acid-d3 is the deuterium labeled DL-Glutamic acid. DL-Glutamic acid is the conjugate acid of Glutamic acid, which acts as a fundamental metabolite. Comparing with the second phase of polymorphs α and β L-Glutamic acid, DL-Glutamic acid presents better stability .
|
-
-
- HY-P3263
-
|
L-Glutamate oxidase
|
Biochemical Assay Reagents
|
Others
|
|
Glutamate oxidase (L-Glutamate oxidase) is a biochemical reagent that can be used as a biological material or organic compound for life science related research. Glutamate oxidase is expressed in E. Coli. Glutamate oxidase can be used to produce α-ketoglutaric acid from l-glutamic acid .
|
-
-
- HY-122373
-
|
|
Aldehyde Dehydrogenase (ALDH)
Drug Derivative
|
Metabolic Disease
|
|
Coprine is an orally active disulfiram (HY-B0240)-like component and an inhibitor of aldehyde dehydrogenase. Coprine is isolated from Coprinus atranentarius. Coprine inhibits low Km aldehyde dehydrogenase in rat liver and increases blood acetaldehyde levels during in vivo ethanol metabolism. Coprine does not inhibit semi-purified low Km aldehyde dehydrogenase from rat liver in vitro. Coprine can be used in studies related to alcoholism .
|
-
-
- HY-14608S6
-
-
-
- HY-N0390S5
-
|
L-glutamic acid 5-amide-1-13C
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
L-Glutamine-1- 13C is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
|
-
-
- HY-N0390S4
-
|
L-glutamic acid 5-amide-5-13C
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
L-Glutamine-5- 13C is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
|
-
-
- HY-135094
-
|
N-Palmitoyl-L-glutamic acid
|
Amino Acid Derivatives
|
Neurological Disease
|
|
Palmitoyl glutamic acid (N-Palmitoyl-L-glutamic acid) is an acyl amino acid with neuroprotective effects . Palmitoyl glutamic acid is used as cosmetic material .
|
-
-
- HY-115685
-
|
|
GABA Receptor
|
Neurological Disease
|
|
3-Methyl-GABA is a potent GABA aminotransferase activator. 3-Methyl-GABA can fit the binding pocket of GABAA receptor (GABAaR). 3-Methyl-GABA can activate L-glutamic acid decarboxylase (GAD). 3-Methyl-GABA has anticonvulsant activity .
|
-
-
- HY-14608S4
-
-
-
- HY-N0390S3
-
|
L-glutamic acid 5-amide-13C5,15N2,d5
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
L-Glutamine- 13C5, 15N2,d5 is the deuterium, 13C-, and 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
|
-
-
- HY-W002169
-
-
-
- HY-W596474D
-
-
-
- HY-W014700
-
|
H-Gly-Glu-OH; Gly-Glu
|
Cholinesterase (ChE)
|
Neurological Disease
|
|
Glycyl-L-glutamic acid is a neurotrophic factor (NF) in vivo, and exerts function of maintenance of AChE content and activity. Glycyl-L-glutamic acid doesn’t act directly on AChE synthesis, and may prevent preganglionic neuronal degeneration .
|
-
-
- HY-14608S10
-
|
|
Apoptosis
iGluR
Ferroptosis
Endogenous Metabolite
|
Neurological Disease
|
|
L-Glutamic acid- 13C2 is the 13C labeled L-Glutamic acid . L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals .
|
-
-
- HY-15121S1
-
|
L-glutamic Acid γ-ethyl amide-13C2,15N2; Nγ-Ethyl-L-glutamine-13C2,15N2
|
DNA/RNA Synthesis
|
Others
|
|
L-Theanine- 13C2, 15N2 (L-Glutamic Acid γ-ethyl amide- 13C2, 15N2) is the 13C- and 15N-labeled L-Theanine (HY-15121). L-Theanine (L-Glutamic Acid γ-ethyl amide) is a non-protein amino acid contained in green tea leaves, which blocks the binding of L-glutamic acid to glutamate receptors in the brain, and with neuroprotective, anticancer and anti-oxidative activities. L-Theanine can pass through the blood–brain barrier and is orally active.
|
-
- HY-W596474C
-
-
- HY-W596474B
-
-
- HY-N0390S15
-
-
- HY-W015240S
-
|
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Metabolic Disease
Inflammation/Immunology
|
|
N-Acetyl-L-glutamic acid-d5 is the deuterium labeled N-Acetyl-L-glutamic acid (HY-W015240). N-Acetyl-L-glutamic acid is a type of glutamic acid that can serve as a component of cell culture media. When combined with media containing inorganic salts, carbohydrates, vitamins, and amino acids, N-Acetyl-L-glutamic acid plays roles in promoting cell growth, enhancing antibody production, etc. N-Acetyl-L-glutamic acid is also an endogenous metabolite that can be found in the brain. Additionally, as an IgE blocker, N-Acetyl-L-glutamic acid can be used in the research of allergic diseases .
|
-
- HY-W041895S
-
|
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Others
|
|
DL-Glutamic acid-d5 is the deuterium labeled DL-Glutamic acid. DL-Glutamic acid is the conjugate acid of Glutamic acid, which acts as a fundamental metabolite. Comparing with the second phase of polymorphs α and β L-Glutamic acid, DL-Glutamic acid presents better stability .
|
-
- HY-14608AR
-
|
|
Reference Standards
iGluR
Apoptosis
Ferroptosis
Endogenous Metabolite
|
Neurological Disease
|
|
L-Glutamic acid (monosodium salt) (Standard) is the analytical standard of L-Glutamic acid (monosodium salt). This product is intended for research and analytical applications. L-Glutamic acid monosodium salt is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium salt has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium salt can be used in the study of neurological diseases .
|
-
- HY-N0390S10
-
-
- HY-137528
-
|
H-Glu(4MbetaNA)-OH; L-glutamic acid γ-(4-methoxy-β-naphthylamide)
|
Aminopeptidase
|
Others
|
|
H-Glu(4MβNA)-OH is a substrate of aminopeptidases (APs) .
|
-
- HY-W104816
-
-
- HY-W011713R
-
|
|
Amino Acid Derivatives
Reference Standards
|
Others
|
|
(4-Aminobenzoyl)-L-glutamic acid (Standard) is the analytical standard of (4-Aminobenzoyl)-L-glutamic acid. This product is intended for research and analytical applications. (4-Aminobenzoyl)-L-glutamic acid is a glutamic acid derivative .
|
-
- HY-B0711R
-
|
N-Carbamyl-L-glutamic acid (Standard)
|
Reference Standards
Others
|
Cancer
|
|
Carglumic Acid (Standard) is the analytical standard of Carglumic Acid. This product is intended for research and analytical applications. Carglumic acid (N-Carbamyl-L-glutamic acid), a functional analogue of N-acetylglutamate (NAG) and a carbamoyl phosphate synthetase 1 (CPS1) activator, is used to treat acute and chronic hyperammonemia associated with NAG synthase (NAGS) deficiency.
|
-
- HY-W011713S
-
|
|
Isotope-Labeled Compounds
|
Others
|
|
N-(4-Aminobenzoyl)-L-glutamic acid-d4 is the deuterium labeled N-(4-Aminobenzoyl)-L-glutamic acid (HY-W011713) . (4-Aminobenzoyl)-L-glutamic acid is a glutamic acid derivative .
|
-
- HY-14608S12
-
|
L-glutamic acid-14C
|
iGluR
Ferroptosis
Apoptosis
|
Neurological Disease
|
|
L-Glutamic acid-14C is L-Glutamic acid (HY-14608) labeled with the radioactive isotope carbon-14. L-Glutamic acid is an excitatory amino acid neurotransmitter and an agonist for all subtypes of glutamate receptors (metabotropic, NMDA, and AMPA). L-Glutamic acid acts as an agonist in the release of DA from dopaminergic nerve terminals and can be used in the study of neurological diseases .
|
-
- HY-W016145S
-
|
|
Isotope-Labeled Compounds
Endogenous Metabolite
iGluR
Ferroptosis
Apoptosis
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
L-Glutamic acid- 13C5 hydrate salt is the 13C labeled L-Glutamic acid hydrate salt. L-Glutamic acid monosodium hydrate is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium hydrate has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium hydrate can be used in the study of neurological diseases. L-Glutamic acid monosodium hydrate acts at ionotropic and?metabotropic glutamate receptors.
|
-
- HY-14608S9
-
-
- HY-W074888
-
|
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
N-Lauroyl-L-glutamic acid is an amino acid derivative with anti-asthmatic activity. N-Lauroyl-L-glutamic acid has been found to improve asthma symptoms in studies. The potential application of N-Lauroyl-L-glutamic acid is mainly focused on the suppression of respiratory diseases. N-Lauroyl-L-glutamic acid may help improve the quality of life of patients .
|
-
- HY-20165
-
-
- HY-W596474H
-
-
- HY-W009262
-
-
- HY-N0390S11
-
-
- HY-159703
-
|
Glutamyl-cysteine; PSSGlu-Cys
|
Endogenous Metabolite
|
Others
|
|
Glu-Cys (Glutamyl-cysteine; PSSGlu-Cys) is a dipeptide composed of L-glutamic acid (HY-14608) and L-cysteine (HY-Y0337) joined by a peptide linkage .
|
-
- HY-100815C
-
|
(±)-AMPA hydrobromide
|
iGluR
|
Neurological Disease
|
|
(RS)-AMPA ((±)-AMPA) hydrobromide is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA hydrobromide does not interfere with binding sites for kainic acid or NMDA receptors .
|
-
- HY-112111A
-
|
|
Biochemical Assay Reagents
|
|
|
Poly-L-Glutamic acid (MW 100000) is a biopolymer composed of L-glutamic acid units. It has the activity of forming stable water-soluble complexes with metal ions and is widely used in the manufacture of biodegradable materials.
|
-
- HY-E70960A
-
-
- HY-E70960
-
-
- HY-W015424R
-
-
- HY-N0390S7
-
|
L-glutamic acid 5-amide-15N2,d5
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
L-Glutamine- 15N2,d5 is the deuterium and 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
|
-
- HY-E70399
-
|
5-Formiminotetrahydrofolate:L-glutamate N-formiminotransferase, FIGLU Enzymes; glutamate formimidoyltransferase
|
Biochemical Assay Reagents
|
Others
|
|
Formimino-L-glutamic acid Transferase can convert aminomethyleneglutamic acid FIGLU and tetrahydrofolate THF into L-glutamic acid and 5-formimino-THF .
|
-
- HY-100815D
-
|
(±)-AMPA monohydrate
|
iGluR
|
Neurological Disease
|
|
(RS)-AMPA ((±)-AMPA) monohydrate is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA monohydrate does not interfere with binding sites for kainic acid or NMDA receptors .
|
-
- HY-100815E
-
|
(±)-AMPA hydrochloride
|
iGluR
|
Neurological Disease
|
|
(RS)-AMPA ((±)-AMPA) hydrochloride is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA hydrobromide does not interfere with binding sites for kainic acid or NMDA receptors .
|
-
- HY-100815BR
-
|
(±)-AMPA (Standard)
|
Reference Standards
iGluR
|
Neurological Disease
|
|
(RS)-AMPA (Standard) is the analytical standard of (RS)-AMPA. This product is intended for research and analytical applications. (RS)-AMPA ((±)-AMPA) is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA does not interfere with binding sites for kainic acid or NMDA receptors .
|
-
- HY-W596474I
-
-
- HY-W596474A
-
-
- HY-W596474E
-
-
- HY-W015240R
-
|
|
Reference Standards
Endogenous Metabolite
|
Metabolic Disease
Inflammation/Immunology
|
|
N-Acetyl-L-glutamic acid (Standard) is the analytical standard of N-Acetyl-L-glutamic acid (HY-W015240). This product is intended for research and analytical applications. N-Acetyl-L-glutamic acid is a type of glutamic acid that can serve as a component of cell culture media. When combined with media containing inorganic salts, carbohydrates, vitamins, and amino acids, N-Acetyl-L-glutamic acid plays roles in promoting cell growth, enhancing antibody production, etc. N-Acetyl-L-glutamic acid is also an endogenous metabolite that can be found in the brain. Additionally, as an IgE blocker, N-Acetyl-L-glutamic acid can be used in the research of allergic diseases .
|
-
- HY-W141952
-
-
- HY-W015240S1
-
|
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Metabolic Disease
Inflammation/Immunology
|
|
N-Acetyl-L-glutamic acid-d4 is the deuterium labeled N-Acetyl-L-glutamic acid (HY-W015240). N-Acetyl-L-glutamic acid is a type of glutamic acid that can serve as a component of cell culture media. When combined with media containing inorganic salts, carbohydrates, vitamins, and amino acids, N-Acetyl-L-glutamic acid plays roles in promoting cell growth, enhancing antibody production, etc. N-Acetyl-L-glutamic acid is also an endogenous metabolite that can be found in the brain. Additionally, as an IgE blocker, N-Acetyl-L-glutamic acid can be used in the research of allergic diseases .
|
-
- HY-135094R
-
|
N-Palmitoyl-L-glutamic acid (Standard)
|
Biochemical Assay Reagents
Reference Standards
Others
|
Neurological Disease
|
|
Palmitoyl glutamic acid (Standard) is the analytical standard of Palmitoyl glutamic acid. This product is intended for research and analytical applications. Palmitoyl glutamic acid (N-Palmitoyl-L-glutamic acid) is an acyl amino acid with neuroprotective effects[1]. Palmitoyl glutamic acid is used as cosmetic material[2].
|
-
- HY-16158R
-
|
Wy-4508 (Standard); Aminocyclohexylpenicillin (Standard); Ciclacillin (Standard)
|
Reference Standards
Bacterial
Antibiotic
|
Infection
|
|
DL-Glutamic acid (Standard) is the analytical standard of DL-Glutamic acid. This product is intended for research and analytical applications. DL-Glutamic acid is the conjugate acid of Glutamic acid, which acts as a fundamental metabolite. Comparing with the second phase of polymorphs α and β L-Glutamic acid, DL-Glutamic acid presents better stability .
|
-
- HY-W041895R
-
|
|
Reference Standards
Endogenous Metabolite
|
Others
|
|
DL-Glutamic acid (Standard) is the analytical standard of DL-Glutamic acid. This product is intended for research and analytical applications. DL-Glutamic acid is the conjugate acid of Glutamic acid, which acts as a fundamental metabolite. Comparing with the second phase of polymorphs α and β L-Glutamic acid, DL-Glutamic acid presents better stability .
|
-
- HY-W766574
-
-
- HY-118758
-
|
γ-Kainic acid-glutamic acid
|
Sodium Channel
|
Neurological Disease
|
|
γ-Kainylglutamic acid (γ-Kainic acid-glutamic acid), a dipeptide derived from kainic and L-Glutamic acids, is a selective antagonist of amino acid induced neuroexcitation with anticonvulsant properties. γ-Kainylglutamic acid inhibits the stimulation of Na + fluxes induced in brain slices by the neuroexcitant N-methyl-D-aspartic acid. γ-Kainylglutamic acid is also effective in protecting mice from picrotoxin-induced convulsions with an EC50 value of 0.17 μmol .
|
-
- HY-176967
-
|
GluCA
|
Drug Derivative
Pregnane X Receptor (PXR)
|
Inflammation/Immunology
|
|
N-Cholyl-L-glutamic acid (GluCA) is a Cholic acid (HY-N0324) conjugated with L-glutamic acid (HY-14608). N-Cholyl-L-glutamic acid increases expression of PXR and downstream PXR-target gene Cyp3a11. N-Cholyl-L-glutamic acid can be used in the research of Crohn's disease .
|
-
- HY-N17468
-
|
|
|
Neurological Disease
|
|
Neocrocin B is a carotenoid crocin. Neocrocin B inhibits L-Glutamic acid (HY-14608)-induced neuronal cell damage in a dose-dependent manner. Neocrocin B can be used in studies related to neuronal injury .
|
-
- HY-W011592
-
|
|
NO Synthase
|
Inflammation/Immunology
|
|
N-Phthaloyl-L-glutamic acid is an orally active anti-inflammatory agent. N-Phthaloyl-L-glutamic acid inhibits Lipopolysaccharides (HY-D1056) (LPS)-induced nitric oxide production in murine spleen cells. N-Phthaloyl-L-glutamic acid does not exhibit significant cytotoxicity in vitro against tumor cells and BALB/c mice spleen cell culture. N-Phthaloyl-L-glutamic acid can be used for the research of inflammation .
|
-
- HY-114844
-
|
H-Phe-Glu-OH
|
Amino Acid Derivatives
|
Others
|
|
L-Phenylalanyl-L-glutamic acid (H-Phe-Glu-OH) is a dipeptide. L-Phenylalanyl-L-glutamic acid is a high-affinity substrate of PEPT2 with a Ki value of 0.022 mM. L-Phenylalanyl-L-glutamic acid exhibits lower affinity for PEPT1, with a Ki value of 0.18 mM .
|
-
- HY-180687
-
-
- HY-180749
-
|
|
Nucleoside Antimetabolite/Analog
|
Metabolic Disease
|
|
L-4-Hydroxyglutamate semialdehyde is a derivative of glutamate semialdehyde, with a hydroxyl group introduced at the 4-position of L-glutamic 5-semialdehyde. L-4-Hydroxyglutamate semialdehyde functions as a metabolite in yeast, mice, and humans, and is functionally associated with L-glutamic 5-semialdehyde, playing a role in arginine and proline metabolism .
|
-
- HY-W736861
-
|
|
iGluR
|
Neurological Disease
|
|
N-Phthaloylglutamic acid is a partial agonist NMDA receptor with a Ki of 13 μM targeting Glu binding-site .
|
-
| Cat. No. |
Product Name |
Type |
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-W141949
-
-
- HY-N13356
-
|
gamma-Glutamylthreonine; H-γ-Glu-Thr-OH; γ-Glu-Thr
|
Bacterial
Peptide-Drug Conjugates (PDCs)
Drug Metabolite
|
Infection
Inflammation/Immunology
|
|
L-gamma-Glutamyl-L-threonine (gamma-Glutamylthreonine; H-γ-Glu-Thr-OH; γ-Glu-Thr) is a dipeptide obtained through the formal condensation of the L-glutamic acid side chain carboxyl group and the L-threonine amino group. L-gamma-Glutamyl-L-threonine is present in high concentrations in human urine and exhibits antibacterial activity against Gram-negative bacterial. L-gamma-Glutamyl-L-threonine is also a flavor compound. Gamma-Glutamylthreonine is a metabolite catalyzed by γ-glutamyl transpeptidase and is associated with immune regulation. Gamma-Glutamylthreonine can be used in research on inflammation and bacterial infections .
|
-
- HY-W011713
-
-
- HY-137874
-
|
|
Peptides
|
Metabolic Disease
Cancer
|
|
L-Glutamic γ-monohydroxamate is an antitumor agent, inhibits cell proliferation. L-Glutamic γ-monohydroxamate selectively inhibits the uptake of L-histidine into microvascular endothelial cell. L-Glutamic γ-monohydroxamate, as a vanadium ligand, activates glucose uptake and metabolism, thus decreases the blood glucose levels in vivo .
|
-
- HY-42364
-
-
- HY-W015424
-
-
- HY-118090
-
|
γ-Glu-Glu; H-γ-Glu-Glu-OH
|
Peptides
|
Others
|
|
L-γ-Glutamyl-L-glutamic acid (γ-Glu-Glu) is the isomer of D-γ-Glutamyl-D-glutamic acid (HY-118090A), and can be used as an experimental control. D-γ-Glutamyl-D-glutamic acid is a poly(γ-glutamic acid) of clusters of D- and D-glutamic acid repeating units in a linear chain .
|
-
- HY-W002169
-
-
- HY-W014700
-
|
H-Gly-Glu-OH; Gly-Glu
|
Cholinesterase (ChE)
|
Neurological Disease
|
|
Glycyl-L-glutamic acid is a neurotrophic factor (NF) in vivo, and exerts function of maintenance of AChE content and activity. Glycyl-L-glutamic acid doesn’t act directly on AChE synthesis, and may prevent preganglionic neuronal degeneration .
|
-
- HY-W011713R
-
|
|
Amino Acid Derivatives
Reference Standards
|
Others
|
|
(4-Aminobenzoyl)-L-glutamic acid (Standard) is the analytical standard of (4-Aminobenzoyl)-L-glutamic acid. This product is intended for research and analytical applications. (4-Aminobenzoyl)-L-glutamic acid is a glutamic acid derivative .
|
-
- HY-20165
-
-
- HY-W009262
-
-
- HY-159703
-
|
Glutamyl-cysteine; PSSGlu-Cys
|
Endogenous Metabolite
|
Others
|
|
Glu-Cys (Glutamyl-cysteine; PSSGlu-Cys) is a dipeptide composed of L-glutamic acid (HY-14608) and L-cysteine (HY-Y0337) joined by a peptide linkage .
|
-
- HY-W015424R
-
-
- HY-W141952
-
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-14608
-
-
-
- HY-N0390
-
-
-
- HY-14608A
-
-
-
- HY-15121
-
-
-
- HY-W015240
-
-
-
- HY-14608R
-
|
|
Structural Classification
Microorganisms
Disease markers
Endocrine diseases
Amino acids
Nervous System Disorder
Endogenous metabolite
Cardiovascular System Disorder
Cancer
Source Classification
|
Reference Standards
Endogenous Metabolite
iGluR
Ferroptosis
Apoptosis
|
L-Glutamic acid (Standard) is the analytical standard of L-Glutamic acid. This product is intended for research and analytical applications. L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases .
IC50 & Target:DA .
In Vitro: L-Glutamic acid (120, 500, 750, 1000 mg/dL) can reduce the harmful effect of lithium on the embryonic development of Xenopus Xenopus .
L-Glutamic acid (2, 5, 10, 20 mM, 24-48 h) can induce neuroexcitotoxicity in neuroblastoma .
In Vivo: L-Glutamic acid (3 g/kg, subcutaneous injection) can promote excitotoxic degeneration of retinal ganglion cells in mice .
L-Glutamic acid (750 mg/kg, intraperitoneal injection) can reduce and inhibit oxidative stress induced by chlorpyrifos (CPF) in rats .
|
-
-
- HY-N0390R
-
|
L-glutamic acid 5-amide (Standard)
|
Structural Classification
Human Gut Microbiota Metabolites
Immune System Disorder
Microorganisms
Disease markers
Endocrine diseases
Amino acids
Nervous System Disorder
Endogenous metabolite
Cardiovascular System Disorder
Cancer
Source Classification
|
Reference Standards
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
|
|
L-Glutamine (Standard) is the analytical standard of L-Glutamine (HY-N0390). This product is intended for research and analytical applications. L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
|
-
-
- HY-15121R
-
-
-
- HY-N13258
-
-
-
- HY-W015424
-
-
-
- HY-14608AR
-
-
-
- HY-B0711R
-
-
-
- HY-W015424R
-
-
-
- HY-W015240R
-
|
|
Microorganisms
Amino acids
Endogenous metabolite
Source Classification
|
Reference Standards
Endogenous Metabolite
|
|
N-Acetyl-L-glutamic acid (Standard) is the analytical standard of N-Acetyl-L-glutamic acid (HY-W015240). This product is intended for research and analytical applications. N-Acetyl-L-glutamic acid is a type of glutamic acid that can serve as a component of cell culture media. When combined with media containing inorganic salts, carbohydrates, vitamins, and amino acids, N-Acetyl-L-glutamic acid plays roles in promoting cell growth, enhancing antibody production, etc. N-Acetyl-L-glutamic acid is also an endogenous metabolite that can be found in the brain. Additionally, as an IgE blocker, N-Acetyl-L-glutamic acid can be used in the research of allergic diseases .
|
-
-
- HY-W041895R
-
-
-
- HY-N17468
-
-
-
- HY-180687
-
-
-
- HY-180749
-
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-N0390S1
-
Maximum Cited Publications
9 Publications Verification
|
|
L-Glutamine- 13C5 is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
|
-
-
- HY-N0390S
-
3 Publications Verification
|
|
L-Glutamine- 15N is the 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
|
-
-
- HY-14608S5
-
1 Publications Verification
|
|
L-Glutamic acid- 13C5 is the 13C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
|
-
-
- HY-N0390S8
-
1 Publications Verification
|
|
L-Glutamine- 15N2 is the 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
|
-
-
- HY-14608S7
-
|
|
|
L-Glutamic acid-d5 is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
|
-
-
- HY-N0390S9
-
3 Publications Verification
|
|
L-Glutamine- 15N-1 is the 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
|
-
-
- HY-14608S8
-
|
|
|
L-Glutamic acid-d3 is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
|
-
-
- HY-14608S3
-
|
|
|
L-Glutamic acid- 13C5, 15N is the 13C- and 15N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
|
-
-
- HY-N0390S2
-
1 Publications Verification
|
|
L-Glutamine-d5 is the deuterium labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
|
-
-
- HY-N0390S6
-
|
|
|
L-Glutamine- 13C5, 15N2 is the 13C- and 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
|
-
-
- HY-14608S
-
|
|
|
L-Glutamic acid- 13C is the 13C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
|
-
-
- HY-14608S2
-
|
|
|
L-Glutamic acid- 15N is the 15N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals .
|
-
-
- HY-14608S1
-
|
|
|
L-Glutamic acid-1- 13C is the 13C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
|
-
-
- HY-15121S
-
|
|
|
L-Theanine-d5 is the deuterium labeled L-Theanine. L-Theanine (L-Glutamic Acid γ-ethyl amide)is a non-protein amino acid contained in green tea leaves, which blocks the binding of L-glutamic acid to glutamate receptors in the brain, and with neuroprotective and anti-oxidative activities. L-Theanine causes anti-stress effects via the inhibition of cortical neuron excitation by oral intake .
|
-
-
- HY-W041895S1
-
|
|
|
DL-Glutamic acid-d3 is the deuterium labeled DL-Glutamic acid. DL-Glutamic acid is the conjugate acid of Glutamic acid, which acts as a fundamental metabolite. Comparing with the second phase of polymorphs α and β L-Glutamic acid, DL-Glutamic acid presents better stability .
|
-
-
- HY-14608S6
-
|
|
|
L-Glutamic acid-5- 13C is the 13C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
|
-
-
- HY-N0390S5
-
1 Publications Verification
|
|
L-Glutamine-1- 13C is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
|
-
-
- HY-N0390S4
-
|
|
|
L-Glutamine-5- 13C is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
|
-
-
- HY-14608S4
-
|
|
|
L-Glutamic acid- 13C5, 15N,d5 is the deuterium, 13C-, and 15-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
|
-
-
- HY-N0390S3
-
|
|
|
L-Glutamine- 13C5, 15N2,d5 is the deuterium, 13C-, and 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
|
-
-
- HY-14608S10
-
|
|
|
L-Glutamic acid- 13C2 is the 13C labeled L-Glutamic acid . L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals .
|
-
-
- HY-15121S1
-
|
|
|
L-Theanine- 13C2, 15N2 (L-Glutamic Acid γ-ethyl amide- 13C2, 15N2) is the 13C- and 15N-labeled L-Theanine (HY-15121). L-Theanine (L-Glutamic Acid γ-ethyl amide) is a non-protein amino acid contained in green tea leaves, which blocks the binding of L-glutamic acid to glutamate receptors in the brain, and with neuroprotective, anticancer and anti-oxidative activities. L-Theanine can pass through the blood–brain barrier and is orally active.
|
-
-
- HY-N0390S15
-
|
|
|
L-Glutamine-d4 (L-Glutamic acid 5-amide-d4) is the deuterium labeled L-Glutamine (HY-N0390). L-Glutamine is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells .
|
-
-
- HY-W015240S
-
|
|
|
N-Acetyl-L-glutamic acid-d5 is the deuterium labeled N-Acetyl-L-glutamic acid (HY-W015240). N-Acetyl-L-glutamic acid is a type of glutamic acid that can serve as a component of cell culture media. When combined with media containing inorganic salts, carbohydrates, vitamins, and amino acids, N-Acetyl-L-glutamic acid plays roles in promoting cell growth, enhancing antibody production, etc. N-Acetyl-L-glutamic acid is also an endogenous metabolite that can be found in the brain. Additionally, as an IgE blocker, N-Acetyl-L-glutamic acid can be used in the research of allergic diseases .
|
-
-
- HY-W041895S
-
|
|
|
DL-Glutamic acid-d5 is the deuterium labeled DL-Glutamic acid. DL-Glutamic acid is the conjugate acid of Glutamic acid, which acts as a fundamental metabolite. Comparing with the second phase of polymorphs α and β L-Glutamic acid, DL-Glutamic acid presents better stability .
|
-
-
- HY-N0390S10
-
|
|
|
L-Glutamine-1,2- 13C2 is the 13C-labeled L-Glutamine. L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells .
|
-
-
- HY-W011713S
-
|
|
|
N-(4-Aminobenzoyl)-L-glutamic acid-d4 is the deuterium labeled N-(4-Aminobenzoyl)-L-glutamic acid (HY-W011713) . (4-Aminobenzoyl)-L-glutamic acid is a glutamic acid derivative .
|
-
-
- HY-W016145S
-
|
|
|
L-Glutamic acid- 13C5 hydrate salt is the 13C labeled L-Glutamic acid hydrate salt. L-Glutamic acid monosodium hydrate is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium hydrate has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium hydrate can be used in the study of neurological diseases. L-Glutamic acid monosodium hydrate acts at ionotropic and?metabotropic glutamate receptors.
|
-
-
- HY-14608S9
-
|
|
|
L-Glutamic acid- 15N,d5 is the deuterium and 15N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
|
-
-
- HY-N0390S11
-
|
|
|
L-Glutamine-2- 13C is the 13C-labeled L-Glutamine. L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells .
|
-
-
- HY-N0390S7
-
|
|
|
L-Glutamine- 15N2,d5 is the deuterium and 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
|
-
-
- HY-W015240S1
-
|
|
|
N-Acetyl-L-glutamic acid-d4 is the deuterium labeled N-Acetyl-L-glutamic acid (HY-W015240). N-Acetyl-L-glutamic acid is a type of glutamic acid that can serve as a component of cell culture media. When combined with media containing inorganic salts, carbohydrates, vitamins, and amino acids, N-Acetyl-L-glutamic acid plays roles in promoting cell growth, enhancing antibody production, etc. N-Acetyl-L-glutamic acid is also an endogenous metabolite that can be found in the brain. Additionally, as an IgE blocker, N-Acetyl-L-glutamic acid can be used in the research of allergic diseases .
|
-
-
- HY-W766574
-
|
|
|
L-Glutamine-5- 13C Hydrochloride is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: